Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil ...

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all ...

Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...

Central Pacific Bank Trust Division lessened its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 82.3% in the 4th ...

Shares of Amgen Inc. AMGN inched 0.75% higher to $261.22 Friday, on what proved to be an all-around favorable trading session ...

Shares of NVIDIA Corp. and Amgen are contributing to the blue-chip gauge's intraday decline, as the Dow was most recently trading 112 points, or 0.3%, lower. NVIDIA Corp.'s shares are down $3.61 ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price dropped by equities research analysts at Wells Fargo & Company ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.